Procedure and Protocol
A transradial artery approach using a 6-French arterial sheath is the routine treatment strategy for AMI at Kaohsiung Chang Gang Memorial Hospital, unless the Allen's test is positive on both sides. A 6-French Kimny guiding catheter (Boston Scientific, Scimed, Inc, Maple Grove, MN, USA) was used for diagnosis and primary PCI. Intra-aortic balloon support was performed via the right femoral arterial approach in patients experiencing acute pulmonary edema associated with unstable physical or hemodynamic conditions.
If diagnostic results justified the use of a distal protective device for the infarct-related artery (IRA) against distal embolization, 19 an adjunctive PercuSurge GuardWire™ device was deployed. (The indications for use have been described in detail in our recent studies. 19, 20 ) Balloon dilatation is first performed after the wire crosses the lesion for a totally occluded IRA. If the lesion size and length could be clearly observed in an IRA following diagnostic coronary angiography, direct stenting was performed during the procedure. In the present study, only the driver stent (Medtronic, Inc, Minneapolis, MN, USA) was used, not drug eluting stents.
Clopidogrel (600 mg loading dose in the emergency room before cardiac catheterization, then 75 mg/daily for maintenance) was given to patients undergoing primary stenting and then aspirin (100 mg orally once daily) indefinitely. Other commonly prescribed medications were angiotensinconverting enzyme inhibitors, statins, β-blockers, isordil/ isosorbidmononitrate, and diuretics.
Left ventricular ejection fraction (LVEF) was obtained by 2-D echocardiography examination on day 2 following AMI.
Blood Sampling and Assessment of Circulating EPC Level by Flow Cytometry
Blood samples were obtained at 8.00 h once within the 24-30 h after primary PCI in the study group and once at the same time for the normal control subjects. A 10-ml sample of blood was drawn from the antecubital vein into a vacutainer containing 3.8% buffered sodium heparin. Mononuclear cells (MNCs) were then isolated by densitygradient centrifugation of Ficoll 400 (Ficoll-Plaque™ plus, Amersham Biosciences, Sweden). The MNCs were washed twice with phosphate-buffered saline (PBS) and centrifuged before incubation with 1 ml blocking buffer for 30 min at 4°C. Cell viability >95% was noted in each group.
The EPCs in peripheral blood were identified by flow cytometry as described in our recent report. 21 To determine the EPC surface markers of CD31/CD34 (E1) and KDR/ CD34 (E2), MNCs (4×10 5 ) were incubated for 30 min at 4°C in a dark room with monoclonal antibodies against kinase insert domain-conjugating receptor (KDR) (Sigma, St Louis, MO, USA), as well as fluorescein isothiocyanate-conjugated CD34 and phycoerythrin (PE)-conjugated CD31 (Becton Dickinson). The control ligand (IgG-PE conjugate) was used to detect any nonspecific associations and define a threshold for glycoprotein binding. For analysis of KDR, the MNCs were further incubated with PE-conjugated anti-mouse antibody created in goats. After staining, the MNCs were fixed in 1% paraformaldehyde. Quantitative 2-color flow cytometric analysis was performed using a fluorescence-activated cell sorter (FACSCalibur™ system; Beckman) ( Figure) . Each analysis included 30,000 cells per sample. The assays for EPCs (E1-2) in each sample were performed in duplicate and mean levels were reported. Intra-assay variability based on repeated measurement of the same blood sample was low, with a mean coefficient of variance of 5.7% in AMI patients and 4.8% in normal subjects.
Serum levels of SDF-1α and IL-10 were measured by duplicate determination using a commercially available ELISA method (R & D, Minneapolis, MN, USA). Intraindividual variability of the SDF-1α and IL-10 levels was assessed in the study patients and control group. The mean intra-assay coefficients of variance were all less than 4.5%.
Definitions and Data Collection
AMI was defined as the presence of typical chest pain exceeding 30 min with ST-se >1 mm in 2 or more consecutive precordial or inferior leads. Unsuccessful reperfusion was defined as failure to achieve normal blood flow after PCI of the IRA. Reperfusion time was defined as the time from chest pain onset to first balloon inflation.
Detailed in-hospital and follow-up data, including age, gender, coronary artery disease risk factors, serial MB fraction of creatine kinase (CK-MB) levels, white blood cell (WBC) counts, creatinine levels, body temperature, Killip score on admission and severity of congestive heart failure (CHF) were collected prospectively and entered into a computer database. Angiographic findings, including collateral circulation and Thrombolysis In Myocardial Infarction (TIMI) flow grades in the culprit coronary artery, were also collected and entered into the database.
Endpoints and Statistical Analysis
The endpoint of the study was the 30-day composite occurrence of MACO, including advanced Killip score (defined as Killip classification ≥3 on presentation) or 30-day mortality. Baseline variables were used for univariate analysis. All significant factors revealed by univariate analysis were further examined by multiple stepwise logistic regression analysis.
Data are expressed as means ± SD. Continuous data were analyzed using the Wilcoxon rank sum test, and categorical data were analyzed by chi-square or Fisher's exact test. Statistical analysis was performed using SAS software for Windows version 8.2 (SAS Institute, Cary, NC, USA). P value <0.05 was considered statistically significant. Controls  Table 1 shows the baseline characteristics of both groups. Age, gender, and creatinine levels did not significantly differ and the serum level of SDF-1α was also similar between study patients and normal control subjects. However, the serum level of IL-10 and the WBC count were substantially higher, and the circulating level of EPCs (E1-2) notably lower in the AMI patients than in the normal control subjects.
Results

Baseline Characteristics of AMI Patients and Normal
Comparison of Baseline Variables, Clinical Findings, Angiographic Results and Outcomes Between Patients
With High and Low SDF-1α Levels (Table 2) Receiver-operating characteristics (ROC) curve analysis revealed that serum level of SDF-1α >1,500 pg/ml was the most powerful predictive factor of 30-day MACO, with a sensitivity of 90.9% and specificity of 80.7%. Accordingly, patients with a serum level of SDF-1α >1,500 pg/ml were classified into Group 1 and those with serum level of SDF-1 ≤1,500 pg/ml were assigned to the low SDF-1α level group (Group 2).
Except for age and the incidence of diabetes mellitus, the 2 groups were similar in gender, cardiovascular risk factors, blood sampling time, WBC counts, peak CK-MB level, and Data are mean ± SD or % (n) of patients. *Continuous variables were analyzed using Wilcoxon rank sum test, and categorical variables by chi-square test or Fisher's exact test, where appropriate; † plasma SDF-1α level >1,500 pg/ml; ‡ plasma SDF-1α level ≤1,500 pg/ml; ¶ Killip score ≥3; § New York Heart Association functional classification ≥3. MI, myocardial infarction; CK-MB, creatine kinase-MB; TIMI, Thrombolysis In Myocardial Infarction; IABP, intra-aortic balloon pump; LVEF, left ventricular ejection fraction; CHF, congestive heart failure. Other abbreviations see in Table 1. incidence of prior MI, previous stroke, re-infarction, mean stent length and size. However, the serum levels of IL-10, creatinine, and EPCs (E1-2) were remarkably higher in Group 1 than in Group 2 patients. Additionally, the incidence of advanced Killip score and advanced CHF (defined as New York Heart Association functional classification ≥3) were notably higher in Group 1 than in Group 2 patients. Angiography revealed that reperfusion time, the incidences of anterior wall MI, multivessel disease, collateral circulation, and the initial or final TIMI flow grade did not significantly differ between the 2 groups. Moreover, there was no significant difference in the frequency of using a PercuSurge device or stenting application, or in the incidence of statin or angiotensin-converting enzyme inhibitor therapy between Group 1 and Group 2 patients. However, LVEF was notably lower in Group 1 than in Group 2 patients. Furthermore, the incidence of using intra-aortic balloon pump support and the 30-day mortality were significantly higher in Group 1 than in Group 2 patients. Although the mean circulating level of EPCs (E1-2) was notably lower in the overall AMI study population (n=129) than in normal control subjects, it was notably higher in Group 1 patients than in normal controls (P<0.05). Additionally, the mean serum level of SDF-1α was similar between the overall AMI patients and normal subjects.
Spearman Rank Correlation Between Circulating EPCs, Serum SDF-1α Level, and Blood Sampling Time (Table 3) To elucidate the potential impact of blood sampling time on the circulating levels of EPCs and SDF-1α, and the relationship between them, Spearman rank correlation analysis was performed and revealed no significant correlation not only between the circulating level of EPCs and blood sampling time, but also between serum level of SDF-1α and blood sampling time. However, a very good and significant correlation between the surface makers (E1-2) of EPCs and a fairly good and significant correlation among serum SDF-1α level and EPC surface makers (E1-2) were noted.
Multiple Stepwise Linear Regression Analysis of Predictors for Increasing Circulating Levels of EPCs (Table 4)
Multiple stepwise linear regression analysis of baseline variables demonstrated that only SDF-1α level and Killip score were significantly and independently predictive of an increased circulating level of EPCs (E1-2).
Factors Associated With 30-Day MACO (Table 5)
Univariate analysis of the baseline variables in Table 2 revealed that the circulating level of EPCs (E1-2), the serum levels of IL-10, creatinine and SDF-1α, low LVEF, and advanced CHF were the most significant factors associated with 30-day MACO. Additionally, old age (≥70 years) and WBC count were also strongly related to increased 30-day MACO.
Independent Predictors of 30-Day Composite Endpoints and Mortality
Multiple stepwise logistic regression analysis (Table 6) revealed that the circulating level of EPCs (E2) was the most powerful independent predictor of 30-day MACO for which the serum level of IL-10 and old age (≥70 years) were also independent predictors. However, the serum level of SDF-1α was not independently predictive of 30-day MACO because of the mutual competition between SDF-1α and the Tables 1,2 .
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circulating level of EPCs (E2), reflected in their good correlation by Spearman rank correlation analysis ( Table 3) .
On the other hand, only advanced Killip score together with WBC count were significantly and independently predictive of 30-day mortality ( Table 7) .
Discussion
Examination of the circulating level of EPCs, the serum levels of SDF-1α and IL-10, and other relevant clinical variables in the patients with AMI undergoing primary PCI in this study lead to several striking clinical implications. Firstly, a good correlation between an increased serum level of SDF-1α and the circulating level of EPCs was found in AMI patients, which highlights the previous finding 6, [8] [9] [10] that SDF-1α is an EPC chemokine involved in the mobilization, incorporation, homing, survival, proliferation, and differentiation of EPCs. Secondly, the mean circulating level of EPCs (E1-2) was notably lower in AMI patients than in normal control subjects, which reinforces previous clinical observational studies [22] [23] [24] demonstrating that the number and migratory activity of circulating EPCs are inversely correlated with the number of risk factors for coronary artery disease and severity of CHF. Finally, another finding of importance in the current study is that the circulating levels of IL-10 and EPCs were independently predictive of 30-day MACO in AMI patients undergoing primary PCI.
Level and Value of Serum SDF-1α and IL-10 Following AMI
SDF-1α, a cytokine secreted by cells within ischemic myocardium, is a potent chemo-attractant for cells expressing CXCR4. [14] [15] [16] 25, 26 Additionally, this chemokine has been identified as an important attractant for stem cells moving to the site of tissue injury, thereby playing an essential role in ischemic organ protection and repair. 14, 16, 27, 28 However, the level and value of SDF-1α is currently unclear in patients with AMI. In the present study, we found that the serum level of SDF-1α did not differ between AMI patients and normal control subjects. Importantly, further analysis revealed that those patients in a serious clinical condition had significantly higher serum levels of SDF-1α than those in a relatively stable clinical condition and in the normal controls. More importantly, the result of this study did not support the serum level of SDF-1α being an independent predictor of 30-MACO in patients with AMI undergoing primary PCI. Our findings can be explained as follows. First, an association between markedly increased circulating levels of chemokines, either pro-inflammatory or anti-inflammatory, and the severity of clinical presentation in AMI patients has been identified. 18, 29 Despite the anti-inflammatory properties 30 of this EPC chemokine, 16 ,31 the elevation in SDF-1α level in the Group 1 patients was more likely a result of acute physiological or pathological stress rather than representing a favorable clinical picture. This hypothesis based on our finding is at least partially supported by recent findings. 16, 18, [29] [30] [31] Second, unstable AMI patients usually have systemic organ ischemia and compromised coronary blood flow. [32] [33] [34] Moreover, SDF-1α expression has been demonstrated to be significantly upregulated in the serum and cardiac tissue of patients with MI. [35] [36] [37] Therefore, we suggest that the increase in the serum SDF-1α concentration is proportional to the severity of systemic organ ischemia and the reduction in coronary blood flow. Accordingly, the results from previous studies [32] [33] [34] [35] [36] [37] also support that observation.
Another important finding in this study is that an increased serum SDF-1α level was significantly correlated with elevated circulating numbers of EPCs, a result that reinforces the findings from previous investigations 6, [8] [9] [10] demonstrating that SDF-1α participates in EPC mobilization and homing to ischemic tissue for subsequent reparation. One of the findings of interest in the present study is that the serum level of SDF-1α was the most important significant independent predictor of an increased circulating level of EPCs and therefore, further supports those previous studies. [35] [36] [37] Pro-inflammatory cytokines participate in the acute-phase response to inflammation following tissue injury. 38 Additionally, anti-inflammatory cytokines act in a feedback loop to inhibit continued pro-inflammatory cytokine production and inflammatory propagation. 39 Thus, it is rational to believe that the levels of anti-inflammatory cytokines are directly proportional to the circulating levels of pro-inflammatory cytokines. Furthermore, the link between an increased level of pro-inflammatory cytokines and an untoward clinical outcome in AMI patients has been established. 29 In the current study, we found that circulating level of IL-10 was strongly and independently predictive of 30-day mortality, which corroborated our recent observational studies 18, 29, 38, 39 demonstrating that an increase in the circulating level of cytokines is associated with untoward clinical outcomes in AMI patients undergoing primary PCI.
Circulating EPC Levels Predict Risk in Patients With AMI Undergoing Primary PCI
There is a growing body of evidence that the number and migratory ability of EPCs are inversely proportional to the number of risk factors for coronary artery disease and severity of CHF. [22] [23] [24] Consistently in the present study we found that those AMI patients who had a high prevalence of coronary risk factors had significantly lower numbers of circulating EPCs than normal subjects.
Although clinical observational studies 6, 7, 40 have shown that the number of circulating EPCs is significantly increased in patients after AMI, no data are available regarding the Tables 1,5 . Tables 1,5. impact of the circulating EPC level on clinical outcome in patients with AMI undergoing primary PCI. The most important finding in the current study is that the circulating level of EPCs was the most significant independent predictor of 30-day clinical outcome. Because previous studies have shown that any acute physical or pathological situation can enhance mobilization of EPCs into the circulation, 21, 40 we speculate that an acute stress usually induces an early and rapid deployment of EPCs into the circulation, to an extent that is directly proportional to the severity of the stress. Accordingly, our findings, in addition to supporting those from previous studies, 21, 40 also extend the results from other investigatiors [5] [6] [7] and, therefore, raise the possibility that the circulating level of EPCs might be a potential biomarker for risk prediction in patients with AMI undergoing primary PCI.
Age is Independently Predictive of 30-Day Mortality After AMI
The current study demonstrated that old age, a traditional risk factor for predicting untoward clinical outcome in AMI patients with or without primary PCI, 29, 34, 41 was independently predictive of 30-day mortality. Therefore, the current finding is consistent with the observations from previous studies. 29, 34, 41 
Study Limitations
Although the serum SDF-1α level was significantly higher in patients with serious clinical presentations, it was not an independent predictor of 30-day MACO, which could be related to the mutual competition between SDF-1α and the circulating level of EPCs (E2), which distorted the statistical significance of SDF-1α for predicting 30-day MACO. Additionally, although SDF-1α and its receptor CXCR4 have been shown to be crucial in the recruitment of EPCs into ischemic tissue, 13, 14, 16 this study did not measure CXCR4 expression in EPCs, so no additional information on the circulating number of CXCR4 + cells is available. Furthermore, the present study made no attempt to elucidate the correlation between the plasma level of vascular endothelial growth factor and the circulating level of EPCs, which has been previously discussed in patients following AMI. 5 
Conclusion
Our observation not only indicates that the serum SDF-1α level may serve as a strong and independent predictor of increased circulating EPCs (E1-2), but it also identifies E2 and IL-10 as 2 major independent predictors of 30-day MACO in ST-se AMI patients undergoing primary PCI. Our results, therefore, provide insights into the possibility of using the circulating EPC and IL-10 levels as biomarkers for risk stratification in AMI patients.
